Gland Pharma Q1 FY27 Results Analysis: PAT Jumps 47%, EBITDA Margin Expands 300 bps
Gland Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,800.27 Cr (+19.57% YoY) and PAT growth of +47.09% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 10, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 1,800.27 Cr (+19.57% YoY) |
| PAT (Q1) | Rs. 316.96 Cr (+47.09% YoY) |
| EBITDA margin | 27.40% (+300 bps YoY) |
| EPS (Q1) | Rs. 19.23 (+47.02% YoY) |
| Market cap | Rs. 43,746.69 Cr |
| CMP | Rs. 2,651.85 |
Quarter Snapshot
Gland Pharma delivered a record Q1 with 19.6% YoY revenue growth and 47% PAT growth, driven by strong US market performance and CDMO expansion. EBITDA margin expanded 300 bps YoY. Post-quarter, the Sugammadex launch provides a near-term catalyst. However, subsidiary losses and raw material cost headwinds in coming quarters temper the outlook.
Key Investment Insights
Key Positives
- Revenue grew 19.57% YoY to Rs.1,800.27 Cr, a record Q1
- PAT grew 47.09% YoY to Rs.316.96 Cr, outpacing revenue growth
- EBITDA margin expanded 300 bps YoY to 27.4%
- CDMO segment grew 20.29% YoY, reaching 49.5% share of revenue
- US market revenue grew 31.80% YoY, driven by volume and new launches
- Post-quarter, Sugammadex received USFDA approval with Day-1 launch
- Net cash position of Rs.3,116 Cr provides balance sheet strength
Risk Factors
- Subsidiary drag of Rs.47.43 Cr on consolidated PAT, indicating Cenexi still loss-making
- Raw material cost headwind expected in Q2-Q3 as inventory buffer depletes
- Canada, Australia & New Zealand market declined 27.74% YoY
- EBITDA margin compressed 200 bps QoQ from Q4 peak of 29.4%
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.